info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Paroxysmal Supraventricular Tachycardia Market Share

ID: MRFR//4462-HCR | 100 Pages | Author: Kinjoll Dey| November 2024

Organizations going for the main share in PSVT focus on the improvement of treatment. This includes putting resources into innovative work to make designated medications or interventional systems that explicitly address the interesting qualities of PSVT, separating their contributions from non-exclusive cardiac medicines.
Leading indicative progressions is pivotal for market positioning. Organizations put resources into state-of-the-art demonstrative innovations for precise and quick identification of PSVT episodes. High level checking gadgets, mobile ECG monitors, and wearable advancements add to ideal determination and upgrade patient consideration, laying out the organization as a forerunner in symptomatic arrangements.
Perceiving the significance of patient awareness, organizations carry out instruction and backing programs for people with PSVT. These drives plan to illuminate patients about the condition, its triggers, and accessible treatment choices. Giving assets to self-management, lifestyle direction, and encouraging groups of people adds to patient fulfillment and brand loyalty.
Expanding into worldwide business sectors is an essential move for organizations looking for expanded share in PSVT arrangements. Observing that cardiac circumstances are common around the world, organizations modify their items and market techniques to meet the requirements of assorted districts. Worldwide expansion expands the client base as well as positions the organization as a worldwide leader in PSVT management.
Organizations focusing on piece of the pie in the PSVT area frequently emphasize minimally invasive interventional methodology. This incorporates the improvement of cutting-edge catheter removal strategies or different methodology that limit patient discomfort and recuperation time. Positioning themselves as pioneers in minimally invasive mediations fortifies their market presence.
Embracing telemedicine and remote checking arrangements is progressively applicable, particularly in constant circumstances like PSVT. Organizations center around creating innovations that consider remote persistent observing, working with appropriate mediation and customized care. Joining of advanced health arrangements adjusts the organization to the developing healthcare landscape and patient inclinations.
Creating vital advertising efforts and powerful branding is fundamental for piece of the pie growth. Organizations utilize different channels to convey the extraordinary incentives of their PSVT arrangements. Underlining variables like development, patient-driven care, and positive results makes important areas of strength for a presence.

Covered Aspects:

Report Attribute/Metric Details
Base Year For Estimation 2022
Forecast Period 2023-2030
Growth Rate 6.90%

Paroxysmal Supraventricular Tachycardia (PSVT) Market Scenario


Paroxysmal Supraventricular Tachycardia Market Size was valued at USD 0.28 Billion in 2023. The Paroxysmal Supraventricular Tachycardia industry is projected to grow from USD 0.30 Billion in 2024 to USD 0.52 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.30% during the forecast period (2024 - 2032). Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate that is caused by electrical impulses originating above the heart. Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heart beating. People suffering from this disorder experience sudden and unexpected occurrence of rapid heart rate that start and stop without warning. A normal heart beats between 60 to 100 beats per minute, but the heart rate of a person suffering from paroxysmal supraventricular tachycardia during an episode may exceed 150–200 beats per minute.


The prevalence of Paroxysmal Supraventricular Tachycardia (PSVT) is unknown but is projected to be around several cases per thousand persons. But, a recent study conducted by Milestone Pharmaceuticals suggested that about 1.7 million patients in the U.S. were suffering from paroxysmal supraventricular tachycardia since the last five years.


The most common types of arrhythmias include atrial fibrillation, atrial flutter, sick sinus syndrome, sinus tachycardia, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and premature ventricular contractions. Moreover, some arrhythmias may lead to more serious medical problems such as sudden stroke or cardiac arrest.


Intended Audience



  • Paroxysmal Supraventricular Tachycardia Drug Manufacturers and Suppliers

  • Paroxysmal Supraventricular Tachycardia Treatment Providers

  • Imaging Device Manufacturers

  • Hospitals and Clinics

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities

  • Market Research and Consulting Service Providers

  • Potential Investors


Figure 1: Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, by Region


 Paroxysmal Supraventricular Tachycardia (PSVT) Market


Paroxysmal Supraventricular Tachycardia (PSVT) Market Segmentation


The Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of type, the Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented into AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT), Paroxysmal Atrial Tachycardia (PAT), and Wolff-Parkinson-White Syndrome (WPW).


On the basis of diagnosis, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into Electrophysiology Study (EPS), stress test, cardiac catheterization, coronary angiography, Electrocardiogram (ECG), echocardiogram, Holter monitor, event monitor, implantable monitor, lab tests, and others. Lab tests are further classified into blood test, urine test, and others.


On the basis of treatment, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into physical maneuvers, medications, catheter ablation, pacemaker, and cardioversion. Medication can be segmented into calcium channel blockers, beta blockers, antiarrhythmic medication, and others. Calcium channel blockers are further divided into diltiazem, verapamil, and others. The antiarrhythmic medication is divided into sotalol, amiodarone, amiodarone, flecainide, propafenone, and adenosine.


On the basis of end-user, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into hospitals and clinics, diagnostic centers, medical research centers, and others.


Research Methodology


 Paroxysmal Supraventricular Tachycardia (PSVT) Methodology


Sources: Annual reports, Press release, White paper, and Company presentation


Paroxysmal Supraventricular Tachycardia (PSVT) Market Regional Analysis


The Paroxysmal Supraventricular Tachycardia (PSVT) market consists of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.


The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of stroke, raising awareness among people, and increasing healthcare expenditure. Coronary artery diseases, heart valve disorders, and heart failures are some of the common causes of heart diseases occurring in adults in North America. Thus, the increasing occurrences of heart failure support the growth of paroxysmal supraventricular tachycardia in this region.


Asia Pacific is estimated to be the most lucrative market for PSVT due to the increasing occurrence of multiple heart disorders in Asia Pacific such as China and others. The growth in the Asian market is fueled by the expanding healthcare infrastructure and presence of untapped market opportunities in this region. This region is considered as an emerging market owing to the increasing number of manufacturers coupled with the increasing market penetration.


The growing prevalence of coronary heart diseases along with the increasing medical tourism that requires surgical procedures are favoring the growth of the market in the Middle East and Africa. In addition, the development of drug delivery technologies, a combination of modern diagnostic techniques, and increasing awareness of various types of heart disorders are similarly supporting the growth of paroxysmal supraventricular tachycardia market.


Paroxysmal Supraventricular Tachycardia (PSVT) Market Key Players


Some of the key players in the Paroxysmal Supraventricular Tachycardia (PSVT) market are: 



  • GlaxoSmithKline PLC (U.K.)

  • Novartis AG (Switzerland)

  • Pfizer, Inc. (U.S.)

  • AstraZeneca PLC (U.K.)

  • Teva pharmaceutical industries (Israel)

  • Sanofi SA (France)

  • Medtronic, Inc. (U.S.)

  • Glenmark Pharmaceuticals (U.S.)

  • St. Jude Medical, Inc. (U.S.)

  • BIOTRONIK SE & Co. KG (U.S.)

  • GE Healthcare (U.S.)

  • Boston Scientific Corporation (U.S.)

  • Abbott Laboratories Inc. (U.S.)

  • (Alcon) Novartis (U.S.)

  • Siemens AG (Germany)

  • Koninklijke Philips N.V. (U.S.)

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.